Mode
Text Size
Log in / Sign up
Phase 3 Completed N=121 Randomized Double-blind Treatment

Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence

Nicotine Dependence · Nicotine Withdrawal
Source: ClinicalTrials.gov NCT00749658 ↗
Enrolled (actual)
121
Serious AEs
0.0%
Results posted
Nov 2020
Primary outcomePrimary: Nicotine Withdrawal and Craving — p=0.07
◆ Published Evidence
No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

The objective of this proposal is to elucidate effects of bupropion SR + varenicline on smoking-cessation related processes in early abstinence using a human laboratory model. A within-subjects design will be used to assess the additive effects of bupropion and varenicline in 48 treatment seeking smokers [bupropion SR (300 mg/day)+placebo, varenicline (2 mg/day+placebo, and bupropion SR (300 mg/day)+varenicline (2 mg/day)]. Outcomes include withdrawal and craving, cognition, stress tolerance, anxiety, the reinforcing effects of smoking, and smoking topography. Hypotheses: We hypothesize that greatest treatment effects will be observed in the bupropion SR+varenicline group followed by varenicline+placebo and bupropion SR+placebo groups.

Outcome Measures

OutcomeResultp-value
PRIMARY
Nicotine Withdrawal and Craving
0.07

Eligibility Criteria

Inclusion Criteria

  • 18 years and up.
  • Smoked at least 10 cigarettes/day for at least 1 year.
  • English speaking and reading.
  • Females who are of childbearing potential must practice effective contraception and meet the following criteria:
  • Are instructed to avoid pregnancy through 30 days after the last dose of study medication.
  • Have a negative urine pregnancy test at baseline.
  • Agree to use of the birth control methods listed: an oral contraceptive agent, an intrauterine device (IUD), an implantable contraceptive (e.g., Norplant), or an injectable contraceptive (e.g., Depo-Provera) for at least one month prior to entering the study and will continue its use through at least 30 days after the last dose of the study medication. A barrier method of contraception (e.g., condom or diaphragm with spermicide) while participating in the study and 30 days after the last dose of study medication.
  • Willingness to not use illicit drugs during study period including marijuana.

Exclusion Criteria

  • Any unstable medical condition.
  • Unstable angina, myocardial infarction, or coronary angioplasty within the past 3 months or an untreated cardiac dysrhythmia.
  • Personal history of seizures.
  • Closed head trauma with any loss of consciousness or amnesia in the last 5 years.
  • A history of closed head trauma with > 30 minutes of loss of consciousness or amnesia or resulting in skull fracture or subdural hematoma/brain contusion.
  • A history of psychosis, bipolar disorder, bulimia or anorexia nervosa.
  • Current depression as assessed by Center for Epidemiologic Studies Depression Scale (CES-D).
  • Medications that might affect the outcome measures of nicotine reward, cognition, anxiety, and stress will also be a basis for exclusion. These medications include psychotropic drugs (i.e., anti-psychotic, anti-depressant, anti-anxiety, or stimulant), anti- hypertensive agents (e.g., beta-blockers), and other drugs that can influence the outcome domains.
  • Active substance abuse other than nicotine.
  • Used an investigational drug within the last 30 days.
  • Are currently using a behavioral or pharmacologic tobacco treatment.
  • Use of bupropion or varenicline in the previous 30 days.
  • Current (past 14 days) use of antipsychotic or antidepressant medications.
  • An allergy to bupropion or varenicline.
  • Untreated hypertension or baseline systolic blood pressure > 180 or diastolic > 100.
  • Impaired kidney function (creatinine clearance < 30).
  • Having plans to leave the immediate geographical area within 2 months.
  • Unwillingness or inability to give written informed consent.

-

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00749658). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search